Search the Newsreel

Pliant Therapeutics Q2 Results: EPS Misses Estimate Despite YoY Improvement

Pliant Therapeutics reported a narrowed Q2 2026 net loss of $22.4 million, down from $43.3 million year-over-year, primarily due to reduced operating expenses after terminating its bexotegrast program. Despite this improvement, the company's EPS of $(0.36) missed analyst estimates of $(0.34). Pliant maintains a …

Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs

Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Pliant Therapeutics (NASDAQ:PLRX) reported a quarterly loss of $0.36 per share, missing analysts' consensus estimates by $0.02. The stock traded down to $1.03, reaching a 12-month low, with a market capitalization of approximately $63.8 million. Analysts currently hold a "Reduce" consensus rating and a …

Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com

This article announces that Pliant Therapeutics Inc. filed a Form 8K on August 11. The filing is brief and does not include further details within the provided text. It is published by Investing.com, a financial markets news source.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Pliant Therapeutics announced its second-quarter 2026 financial results and a corporate update, highlighting strong enrollment in its FORTIFY Phase 1b trial for PLN-101095, an oncology drug. The company also reported positive Phase 1 biomarker data for PLN-101095 and appointed two seasoned oncology drug development …

Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves

Pliant Therapeutics (PLRX) reported a significantly narrowed net loss of $22.4 million for the quarter ended June 30, 2026, compared to $43.3 million a year prior, primarily due to reduced research and development and general and administrative expenses following a 2025 restructuring and program …

Pliant Therapeutics Inc (PLRX) Stock News Today

Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Pliant Therapeutics Inc (PLRX) has an earnings forecast score of 5.60, ranking 138 out of 156 in the Pharmaceuticals industry. The average price target set by analysts is $3.50, with a potential upside of 138.10%. Analysts currently hold a "Hold" rating for the stock, …

Pliant Therapeutics, Inc. expected to post a loss of 34 cents a share - Earnings Preview

Pliant Therapeutics, Inc. is projected to report a loss of 34 cents per share. This information comes from a Refinitiv earnings preview. The full article is available on TradingView, which provides access to Reuters news and other sources.

Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis

Pliant Therapeutics Inc (PLRX) has a current valuation score of 8.36, ranking 59 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is -0.57, which is significantly below its recent high and above its recent low. Other key valuation metrics like P/B, …

Pliant Therapeutics (PLRX) Expected to Release Quarterly Earnings on Thursday

Pliant Therapeutics, Inc. $PLRX Stock Position Raised by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC significantly increased its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 3,402.0% in the first quarter, now owning 4.17% of the company's stock valued at $3.26 million. Despite this increase in institutional ownership, analyst sentiment remains cautious, with an average rating …

PLRX|Pliant Therapeutics Inc|Price:1.075|Chg%:-0.005

This article provides a comprehensive stock analysis of Pliant Therapeutics Inc (PLRX) by TradingKey, assigning it a score of 5.48/10. Key insights indicate stable fundamentals, high growth potential, and a 'fairly valued' assessment within the Pharmaceuticals industry. While institutional ownership is very high, the …

Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis

Pliant Therapeutics Inc (PLRX) has a weak financial status and low operating efficiency, ranking 150 out of 155 in the pharmaceuticals industry with a financial score of 5.80. The report indicates that relevant financial data regarding cash, assets, revenue, and profits have not yet …

Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pliant Therapeutics Inc (PLRX), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 2.95, ranking 141 out of 155 in the Pharmaceuticals industry, and it is …

Pliant Therapeutics Inc (PLRX) Income Statement

This article provides the quarterly and annual income statements for Pliant Therapeutics Inc (PLRX), detailing financial performance metrics such as total revenue, operating expenses, net income, and earnings per share. It allows users to gain insights into the company's operational efficiency and trends over …

Pliant Therapeutics Inc (PLRX) Cash Flow

This article provides a detailed cash flow statement for Pliant Therapeutics Inc (PLRX), covering quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions (FAQs) about different types of cash flow, such as operating, investing, and financing cash …

Pliant Therapeutics Inc (PLRX) Institutional Confidence

Pliant Therapeutics Inc (PLRX) has an institutional shareholding score of 7.00, ranking 50th out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 81.81%, which is a quarter-over-quarter decrease of 4.56%. James Simons is the largest institutional shareholder, holding 2.99% of …

PLRX|Pliant Therapeutics Inc|Price:1.090|Chg%:+0.010

Pliant Therapeutics Inc. (PLRX) is a late-stage biotechnology company developing therapies for fibrosis and related diseases. The company's stock is currently priced at $1.090 with high institutional ownership and is considered fairly valued. Analysts generally rate it as "Hold" with a target price of …

Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Pliant Therapeutics Inc (PLRX), noting that specific data for FY2024 and FY2025 has not yet been disclosed by the company. It indicates that the company's revenue from the United States is currently 0.00. The article is largely …

Pliant Therapeutics (NASDAQ:PLRX) Trading Down 7% - Here's Why